About OncoStem
OncoStem is a company based in Bengaluru (India) founded in 2011 by Manjiri Bakre. OncoStem has raised $9 million across 2 funding rounds from investors including Peak XV Partners and Artiman. The company has 17 employees as of April 08, 2024. OncoStem operates in a competitive market with competitors including Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Unity Biotechnology, among others.
- Headquarter Bengaluru, India
- Employees 17 as on 08 Apr, 2024
- Founders Manjiri Bakre
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Oncostem Diagnostics Private Limited
- Date of Incorporation 15 Mar, 2011
- Jurisdiction Bangaluru, Karnataka, India
-
Annual Revenue
$709.5 K (USD)-43.66as on Mar 31, 2023
-
Net Profit
-$244.33 K (USD)-2016.27as on Mar 31, 2023
-
EBITDA
-$233.29 K (USD)-3613.18as on Mar 31, 2023
-
Total Equity Funding
$9 M (USD)
in 2 rounds
-
Latest Funding Round
$6 M (USD), Series A
Sep 06, 2017
-
Investors
Peak XV Partners
& 1 more
-
Employee Count
17
as on Apr 08, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of OncoStem
OncoStem has successfully raised a total of $9M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $6 million completed in September 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in OncoStem
OncoStem has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Peak XV Partners and Artiman.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm investing in technology and healthcare sectors.
|
Locked | Locked | Locked | |
|
Venture capital firm investing in startups and providing support programs.
|
Locked | Locked | Locked |
Investor details for OncoStem
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by OncoStem
Investment portfolio details for OncoStem
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - OncoStem
Detailed financials for OncoStem
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Oncostem Comparisons
Peer comparison for OncoStem
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of OncoStem
OncoStem operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Unity Biotechnology, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| Locked | Locked | Locked |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for aging diseases are developed by targeting senescent cells.
|
|
| Locked | Locked | Locked |
Diagnostic services are provided through laboratories and radiology units.
|
Detailed competitors of OncoStem
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Oncostem
Complete news archive for OncoStem
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about OncoStem
OncoStem was founded in 2011.
OncoStem is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
Manjiri Bakre is the current CEO of OncoStem. They have also founded this company.
OncoStem is a funded company, having raised a total of $9M across 2 funding rounds to date.
As of Apr 08, 2024, the latest employee count at OncoStem is 17.
Annual revenue of OncoStem is $709.5K as on Mar 31, 2023.
OncoStem was founded in 2011 in Bengaluru, India, and operates in the oncology diagnostics sector. Prognostic tests for cancer are developed, with the flagship product CanAssist-Breast employing an AI-based statistical model to assess breast cancer recurrence risk. Additional tumor details are provided to support customized treatment decisions. The company focuses on enhancing clinical outcomes through precise risk stratification.
OncoStem's top competitors include Juno Therapeutics, Poseida Therapeutics and Denali Therapeutics.
OncoStem has 2 investors. Key investors include Peak XV Partners, and Artiman.